Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SOLESENCE, INC. Director's Dealing 2021

Nov 24, 2021

33563_dirs_2021-11-24_75ec7fde-eead-4375-b598-256a5e7fb82f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2021-11-22

Reporting Person: Cureton Kevin (Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-11-22 Common Stock M 11668 $0.415 Acquired 37318 Direct
2021-11-22 Common Stock S 11668 $3.9204 Disposed 25650 Direct
2021-11-24 Common Stock M 12332 $0.415 Acquired 37982 Direct
2021-11-24 Common Stock M 12393 $0.52 Acquired 50375 Direct
2021-11-24 Common Stock S 24725 $3.77 Disposed 25650 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-11-22 Common Stock (right to purchase) $0.415 M 11668 Disposed 2023-02-14 Common Stock (11668) Direct
2021-11-24 Common Stock (right to purchase) $0.415 M 12332 Disposed 2023-02-14 Common Stock (36332) Direct
2021-11-24 Common Stock (right to purchase) $0.52 M 12393 Disposed 2024-02-13 Common Stock (75000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Common Stock (right to purchase) $0.44 2025-02-18 Common Stock (50000) 50000 Direct
Common Stock (right to purchase) $0.42 2026-02-23 Common Stock (43500) 43500 Direct
Common Stock (right to purchase) $0.68 2027-02-21 Common Stock (50000) 50000 Direct
Common Stock (right to purchase) $0.82 2028-05-23 Common Stock (80000) 80000 Direct
Common Stock (right to purchase) $0.51 2029-05-22 Common Stock (16500) 16500 Direct
Common Stock (right to purchase) $0.45 2027-06-18 Common Stock (90000) 90000 Direct

Footnotes

F1: This line item represents the 1st sale of 11,668 shares of a total grant of 48,000 shares, leaving a balance of 36,332 shares remaining relating to this grant.

F2: This line item represents the 2nd sale, of 12,332 shares of a total initial grant of 48,000 shares, leaving a balance of 24,000 shares remaining relating to this grant.

F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.